Juliana Oliveira da Silva Lopes Pereira

Ms. Juliana Oliveira da Silva Lopes Pereira

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2025 in ACS Omega
Verified
Journal Article
Open access
JVJoão Vitor Vicente-Da-Silva
João Vitor Vicente-Da-Silva
JPJuliana Oliveira da Silva Lopes Pereira
Juliana Oliveira da Silva Lopes Pereira
FCFlávia Carmo
Flávia Carmo
BPBeatriz Ferreira de Carvalho Patricio
Beatriz Ferreira de Carvalho Patricio
The skin plays a crucial role in the body's homeostasis through its thermoregulation functions, metabolic activity, and, mainly, its barrier function. Once this system has its homeostasis disturbed, through the promotion of tissue discontinuity, an injury happens and a restoration process starts. Different products can be used to promote, accelerate, or stimulate the healing process, such as hydrogels, emulsions, and ointments (main conventional formulations). Despite the historical use and wide market and consumer acceptance, new systems emerged for wound management with the main challenge to overcome conventional form limitations, in which nanosystems are found, mainly nanobased emulsion forms (nano- and microemulsions, NE and ME). Here, we discuss the skin function and wound healing process, highlighting the cellular and molecular processes, the different wound classifications, and factors that affect physiological healing. We also investigated the recent patents (2012-2023) filed at the United States Patent and Trademark Office, where we found few patents for conventional forms (hydrogels = 5; emulsions = 4; ointments = 6) but a larger number of patents for nanobased emulsions filed in this time (NE = 638; ME = 4,072). Furthermore, we address the use of nanobased emulsions (NE and ME) and their particularities, differences, and application in wound treatment. This work also discusses the challenges, bottlenecks, and regulatory framework for nanosystems, industrial, academic, and government interest in nanotechnology, and future perspectives about this key factor for the nanosystems market and consumer acceptance.

3 December 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
BPBeatriz Ferreira de Carvalho Patricio
Beatriz Ferreira de Carvalho Patricio
JPJuliana Oliveira da Silva Lopes Pereira
Juliana Oliveira da Silva Lopes Pereira
MSMichelle Sarcinelli
Michelle Sarcinelli
Bianca MoraesBianca Moraes
Bianca Moraes
HRHelvécio Vinícius Antunes Rocha
Helvécio Vinícius Antunes Rocha
Cassiano Felippe Gonçalves-de-AlbuquerqueCassiano Felippe Gonçalves-de-Albuquerque
Cassiano Felippe Gonçalves-de-Albuquerque
Fungal diseases are a significant cause of morbidity and mortality worldwide, primarily affecting immunocompromised patients. Aspergillus, Pneumocystis, and Cryptococcus are opportunistic fungi and may cause severe lung disease. They can develop mechanisms to evade the host immune system and colonize or cause lung disease. Current fungal infection treatments constitute a few classes of antifungal drugs with significant fungi resistance development. Amphotericin B (AmB) has a broad-spectrum antifungal effect with a low incidence of resistance. However, AmB is a highly lipophilic antifungal with low solubility and permeability and is unstable in light, heat, and oxygen. Due to the difficulty of achieving adequate concentrations of AmB in the lung by intravenous administration and seeking to minimize adverse effects, nebulized AmB has been used. The pulmonary pathway has advantages such as its rapid onset of action, low metabolic activity at the site of action, ability to avoid first-pass hepatic metabolism, lower risk of adverse effects, and thin thickness of the alveolar epithelium. This paper presented different strategies for pulmonary AmB delivery, detailing the potential of nanoformulation and hoping to foster research in the field. Our finds indicate that despite an optimistic scenario for the pulmonary formulation of AmB based on the encouraging results discussed here, there is still no product registration on the FDA nor any clinical trial undergoing ClinicalTrial.gov.